A new vaccine for respiratory infections in adults 60 and older
Part of Infections clinical trials.
This trial tests a new vaccine designed to help protect older adults from infections that can affect breathing. You might be able to join if you're in generally good health and meet the other requirements listed below.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 60 years of age or older.
- You are in reasonably good health or have chronic conditions that are well-controlled.
- You have not had a BCG vaccine (a tuberculosis vaccine) in the last 10 years.
- You are willing to follow study procedures, including attending all visits and avoiding elective surgery during the study.
- You have not taken part in another research study in the last 3 months and will not take part in another for the next 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new RSV vaccine for people aged 60 and above. RSV is a common virus that can cause serious breathing problems in older adults. The study will see if the vaccine is safe and helps protect you from RSV.
This trial tests an experimental vaccine for respiratory syncytial virus (RSV), a common virus that can cause serious lung infections, especially in older adults. The study checks if the vaccine is safe and how the body responds to it.
This study tests a new tuberculosis (TB) vaccine (ID93+GLA-SE) in healthy adults aged 55 to 74. It aims to see if the vaccine is safe and can help protect against TB, especially in people who may have latent (inactive) TB infection.
This trial tests an experimental vaccine to protect older adults against respiratory syncytial virus (RSV), a common virus that can cause serious lung infections. It looks at whether the vaccine is safe and how well it boosts immunity. If you are healthy and over 60, you might be able to join.
This trial tests a new RSV vaccine in two phases. First, it will be given to healthy adults 18 and older to check safety. Then, it will be studied in adults 50 and older, including those with stable health conditions, to see if it helps protect against RSV, a common virus that can cause serious breathing problems in older people.
This trial tests a booster dose of an experimental RSV vaccine (SCB-1019T) in healthy adults aged 60-85 who have already received the approved RSV vaccine AREXVY. The goal is to see if the booster is safe and boosts your immune system.
Hear when a new Respiratory Syncytial Virus Infection Prevention trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.